MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference

MediWound (MDWD)/b) will participate in a fireside chat at the H.C.

Rhea-AI Summary

MediWound (MDWD)/b) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 2:00 p.m. ET.The event will be held at the Lotte New York Palace Hotel in New York City, moderated by Swayampakula Ramakanth of H.C. Wainwright. A live webcast will be accessible on MediWound’s website under Investors > Events & Presentations.

Market Context

MDWD's August 13 earnings reaction was -2.73%. The conference notice supplies timing rather than ope...

Analysis

MDWD's August 13 earnings reaction was -2.73%. The conference notice supplies timing rather than operating results; recent insider activity was net selling, while follow-up disclosures from the event could distinguish scheduling from new fundamentals.

Key Figures

Conference edition: 28th Conference dates: September 14–16, 2026 Fireside chat date: September 14, 2026 +1 more

4 metrics

Conference edition 28th H.C. Wainwright Global Investment Conference

Conference dates September 14–16, 2026 H.C. Wainwright Global Investment Conference

Fireside chat date September 14, 2026 MediWound fireside chat

Fireside chat time 2:00 p.m. ET September 14, 2026

Historical Context

5 past events · Latest: Aug 13 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 13	Second-quarter earnings	Negative	-2.7%	Lower revenue and wider operating losses accompanied reaffirmed full-year guidance
Jul 29	Earnings date notice	Neutral	-1.9%	Company scheduled second-quarter results and a management conference call
May 27	First-quarter earnings	Negative	-14.1%	Revenue declined and net loss widened despite reaffirmed full-year guidance
May 07	Earnings date notice	Neutral	-0.6%	Company announced first-quarter results date and webcast arrangements
Apr 13	Expert consensus update	Positive	-1.1%	U.S. expert consensus supported earlier less-invasive chronic-wound debridement

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent MDWD news reactions were negative across all five events, including both earnings reports and routine earnings-date notices.

Key Terms

biologic, eschar, debridement

3 terms

biologic medical

"The company’s FDA-approved biologic, NexoBrid®, is indicated"

A biologic is a medicine made from living cells or organisms—such as proteins, antibodies or vaccines—rather than being chemically synthesized. Investors watch biologics closely because they are expensive and complex to develop and manufacture, often enjoy strong market pricing and protections, and face unique regulatory and supply risks; think of them like handcrafted specialty goods versus mass-produced items with higher potential reward and higher production risk.

eschar medical

"for the enzymatic removal of eschar in thermal burns"

A dry, dark scab of dead tissue that forms over a wound or ulcer when skin cells and blood supply have been damaged; it’s the crusty layer doctors inspect to judge healing or infection. For investors, eschar matters in healthcare contexts because its presence, size, or changes can signal how well a treatment, device or wound-care product is working, or indicate complications that may affect clinical outcomes and regulatory reviews.

debridement medical

"EscharEx®, is an investigational therapy for the debridement of chronic wounds"

Debridement is the medical removal of dead, infected, or damaged tissue and foreign material from a wound to promote healing, similar to pruning dead branches so new growth can flourish. For investors, it matters because how debridement is performed — by drugs, devices, dressings, or procedures — affects clinical outcomes, product demand, reimbursement decisions, regulatory approval pathways, and the financial prospects of companies offering those solutions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MediWound to Present at the H.C. Wainwright 28^th Annual Global Investment Conference

YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will take place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.

The fireside chat, moderated by Swayampakula Ramakanth, Managing Director and Senior Healthcare Analyst at H.C. Wainwright, is scheduled for Monday, September 14, 2026, at 2:00 p.m. ET.

A live webcast of the fireside chat will be available here and on MediWound’s website under the Events & Presentations page in the Investors section.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx^®, is an investigational therapy for the debridement of chronic wounds, with the potential to become, if approved, a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).

MediWound Contacts:
Hani Luxenburg Chief Financial Officer MediWound Ltd. ir@mediwound.com		Daniel Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com

FAQ

When will MediWound (MDWD) present at the H.C. Wainwright 28th Annual Global Investment Conference?

MediWound’s CEO, Ofer Gonen, is scheduled to participate in a fireside chat on Monday, September 14, 2026, at 2:00 p.m. ET during the H.C. Wainwright 28th Annual Global Investment Conference.

Where is the H.C. Wainwright 28th Annual Global Investment Conference featuring MediWound (MDWD) being held?

The conference, where MediWound’s CEO will join a fireside chat, will take place on September 14–16, 2026, at the Lotte New York Palace Hotel in New York City.

How can investors access the MediWound (MDWD) fireside chat webcast from the H.C. Wainwright conference?

A live webcast of the fireside chat will be available via an online link and on MediWound’s website under the Investors section, on the Events & Presentations page.

Who will represent MediWound (MDWD) at the H.C. Wainwright 28th Annual Global Investment Conference fireside chat?

MediWound’s Chief Executive Officer, Ofer Gonen, will participate in the fireside chat, which will be moderated by Swayampakula Ramakanth, Managing Director and Senior Healthcare Analyst at H.C. Wainwright.